SEC Form 4

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to)
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average bur	den								
hours per response:	0.5								

ours per response:	0.5

			2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]		lationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner			
(Last) (Eirst) (Middlo)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/30/2007		Officer (give title below)	Other (specify below)		
(Street) CAMBRIDGE	Street)		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V Amount (A) or (D) P		Price	Transaction(s) (Instr. 3 and 4)		(1130.4)		
Common Stock	05/31/2007		S ⁽¹⁾		1,500	D	\$51.91	2,250	D	
Common Stock	05/31/2007		A		2,300	Α	\$0.00 ⁽²⁾	4,550	D	
Common Stock	05/31/2007		Α		2,300	Α	\$0.00 ⁽²⁾	6,850	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$52.22	05/31/2007		A		5,950		(3)	05/30/2017	Common Stock	5,950	(2)	5,950	D	
Stock Option (right to buy)	\$52.22	05/31/2007		A		5,950		(3)	05/30/2017	Common Stock	5,950	(2)	5,950	D	

Explanation of Responses:

1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

2. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

3. Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.

Remarks:

Robert A. Licht, Attorney in fact for Bruce Ross

06/01/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.